Cure with SR18662 substantially reduces advancement and proliferation of CRC cells. SR18662 displays improved efficacy in minimizing viability of multiple CRC cell traces. Flow cytometry Investigation pursuing SR18662 therapy reveals an increase in cells captured in both S or G2/M phases on the mobile cycle and a substantial boost in the number of